Understanding and Alleviating Healthcare System Pressure: A Conceptual Framework

By Staff Writer

February 14, 2024

Introduction:

The COVID-19 pandemic has highlighted the devastating effects of resource scarcity in healthcare systems. This emphasises the need to understand and ease Healthcare System Pressure (HCSP). While there’s no official HCSP definition, the Office of Health Economics (OHE) has developed and examined a conceptual framework for HCSP. It includes a broad definition and concepts of HCSP, strategies to lessen HCSP, and a system for metric categorisation.

Understanding Healthcare System Pressure:

Long before the COVID-19 pandemic, healthcare systems were feeling the strain. This is evident in the UK, where increasing waiting lists and treatment times are common. Yet, the term ‘pressure’ lacks a clear definition in the healthcare context. When healthcare systems face strain, they behave differently than in normal conditions. This strain could lead to an inability to provide emergency care or delay planned care. Moreover, the quality of care might suffer due to continuous pressure on staff. This can lead to staff burnout and poorer health outcomes for patients.

The Conceptual Framework of HCSP:

The primary exposure of hospital settings to increased patient demand in the event of seasonal diseases or pandemics was the driving force for the decision to concentrate on HCSP in hospital settings. It was the findings of the review that served as the basis for the construction of each individual component of the conceptual framework. They also conducted a ‘proof-of-concept’ exercise utilising expert interviews from Germany, Italy and the UK to test the comprehensiveness and usefulness of this framework, using respiratory syncytial virus (RSV) and Clostridioides difficile (C. difficile) infections as case studies.

Universally Accepted Definition of HCSP:

HCSP can affect different types of resources that can be categorised into ‘staff’ (i.e., labour resources), ‘stuff’ (i.e., durable equipment) and ‘structures’ (physical infrastructure within the hospital). A resource has a usable capacity, which is the amount of capacity available for production in normal circumstances. The usable capacity can be split into utilised capacity, which is actually used for production, and idle capacity, which remains unused. Using the concepts of resources, capacity, and utilisation, HCSP can be described as occurring when the demand determining the utilised capacity of a resource exceeds its usable capacity (Figure 1).

Alleviating HCSP:

Keeping bed occupancy below 85% is crucial for hospitals to operate safely and effectively, as seen in the English National Health System (NHS). This framework identifies two main actions to alleviate HCSP: increasing the usable capacity to accommodate higher demand levels and expanding the usable capacity as a pressure-mitigating action. These actions are linked to the concept of surge capacity, which is predominantly applied within the field of disaster management.

Classifying HCSP Metrics:

The OHE found no consensus on the metrics of HCSP and its opportunity costs. However, for each resource, HCSP can be measured using usable and utilised capacity metrics. Routinely collected key performance indicators (KPIs) in hospital finance, procedures, and staff provide multiple pressure measurement alternatives. Some KPIs directly measure resource utilisation (e.g. bed occupancy and average length of stay), while others indirectly indicate pressure (e.g. staff turnover or waiting times). This can impact quality indicators and outcomes, such as mortality rates.

Conclusion:

The proposed framework may have beneficial and practical applications. We could use the HCSP formulation to evaluate health technologies that reduce pressure on the healthcare system. This evaluation forms part of the health technology assessment (HTA). The goal of HTA is to guide the efficient use of limited healthcare resources. This becomes crucial in high-strain situations like those seen in the NHS, leading to elective surgery cancellations and potential medical care rationing. Traditional HTA approaches may underestimate HCSP-easing health innovations such as vaccinations. This is because of the large elective care backlogs and the high potential cost of delayed treatment.

Reference url

Recent Posts

oral GLP-1 medication
    

Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

🌟 Ready for a breakthrough in diabetes management?

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a successful Phase 3 trial, showing remarkable efficacy in lowering A1C levels and promoting substantial weight loss. As the first oral small molecule GLP-1 receptor agonist, it offers a promising alternative to conventional injectable treatments, potentially improving patient adherence and access.

Dive into the details of this exciting development and what it means for the future of diabetes care!

#SyenzaNews #HealthTech #Innovation #Pharmaceuticals

pediatric thyroid cancer risk
    

Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from a California Study

🌟 Are we overlooking environmental risks in pediatric cancer?

Recent research highlights a troubling link between perinatal exposure to PM2.5 and outdoor artificial light and the increased risk of pediatric thyroid cancer. This pivotal study sheds light on how environmental factors play a critical role in childhood health, particularly among vulnerable populations.

Dive into this important discussion on how addressing these environmental exposures may reduce pediatric thyroid cancer and improve health outcomes for future generations.

#SyenzaNews #EnvironmentalHealth #HealthPolicy #Innovation

capivasertib cost-effectiveness
      

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.